The European Parliament’s Public Health Committee on Monday approved a new suite of measures aimed at bolstering the availability and security of critical medicines across the bloc.
The move signals a growing realisation in Brussels that Europe’s pharmaceutical supply chains remain perilously vulnerable — not just to market forces, but to geopolitical upheaval and industrial bottlenecks.
The draft legislation, adopted by 27 votes to one with eight abstentions, lays the groundwork for a fundamental recalibration of Europe’s pharmaceutical industrial strategy. At its core is a recognition that over half of all reported medicine shortages stem from manufacturing problems, including a lack of active ingredients and an over-reliance on suppliers beyond the EU’s borders.
For years, shortages of essential Medicines — from antibiotics and insulin to pain treatments — have wreaked havoc on hospitals, care homes and pharmacies across member states. What was once seen as an occasional disruption has hardened into a structural weakness within the European health system. The Parliament’s report, however, marks a turning point: it reframes pharmaceutical production not merely as a commercial sector but as a strategic asset of public health and economic security.
Central to the Parliament’s proposals is the creation of so-called “strategic projects” within the EU to expand manufacturing capacity for critical medicines and their key substances. These initiatives, supported by easier access to dedicated funding and clearer regulatory assessment pathways, are intended to attract investment and modernise facilities across the continent.
Linking industrial policy to health resilience is a direct response to years of warnings from experts and health officials alike. The European Commission itself first proposed a Critical Medicines Act earlier in 2025, recognising that entrenched supply chain dependencies — particularly for active pharmaceutical ingredients — had left Europe susceptible to disruptions.
Diversification and Collaboration
Beyond scaling up capacity, MEPs have emphasised the importance of supply chain diversification. Current procurement frameworks, they argue, leave too many member states dependent on singular suppliers, some of whom operate outside the EU regulatory orbit. The committee’s text therefore advocates for public procurement provisions that allow contracts to be awarded to multiple suppliers of the same product, ensuring production is distributed across different manufacturers and geographical locations within the Union.
This approach also brings with it a fresh impetus for collaborative procurement among member states. The idea is straightforward: national health ministries and procurement agencies work jointly — or alongside the European Commission — to secure supplies of high-cost, specialised or rare medicines. In doing so, member states can wield greater negotiating leverage and mitigate the risk that smaller countries, in particular, are left behind during times of scarcity.
The Parliament’s report encourages joint procurement involving at least five EU countries working with the Commission, and smaller collaborative groups comprising three or more states. Such frameworks are already familiar from vaccine purchases during the Covid-19 pandemic; proponents argue they should become a permanent fixture of EU health security policy.
Another pillar of the proposals is the establishment of an EU-level coordination mechanism for national stockpiles and contingency reserves of critical medicines. In a crisis — for example, a sudden shortage of a life-saving antibiotic — the Commission would, as a last resort, have the authority to redistribute supplies from one country’s stockpile to another’s. This provision, while controversial among some national capitals protective of their sovereignty, is deemed necessary by MEPs to ensure rapid and equitable responses to supply disruptions.
MEP Tomislav Sokol framed the committee’s decision as “a defining moment for Europe’s health security”, emphasising that the report’s measures would reduce dependence on a limited number of external suppliers and foster a more resilient, independent pharmaceutical ecosystem. He added that the measures would ensure “fair access to essential medicines such as antibiotics, insulin and pain treatments” throughout the EU.
Towards Negotiations with Member States
Parliament’s position now heads toward final adoption in the January 2026 plenary session, after which formal negotiations with EU governments — sitting in the Council — will begin. The result of those negotiations will determine the final shape of the EU’s critical medicines regime.
Brussels’ broader strategy echoes similar industrial policy currents elsewhere in Europe. National and regional leaders have increasingly warned that health security must be treated with the same strategic gravity as energy, defence or digital sovereignty. The European Committee of the Regions, for example, unanimously called in December for health security to be formally embedded in the EU’s collective defence paradigm, arguing that medicine supply vulnerabilities pose as much of a strategic risk as cyber threats or energy disruptions.
Critics of the package caution that heavy-handed procurement rules and state-led intervention risks distorting markets and stifling innovation. The pharmaceutical industry, historically protective of intellectual property and flexible market access, may resist elements that could, in its view, tip the balance too far from market incentives towards regulatory control.
Yet proponents counter that the raison d’être of such rules is not to undermine innovation but to safeguard public health. In an era of geopolitical fragmentation, industrial concentration and global competition for scarce resources, a strategy that ensures European patients have reliable, uninterrupted access to vital medicines is increasingly seen as indispensable.
Should the Parliament’s vision withstand negotiations and political scrutiny, it would represent a paradigm shift: treating medicines not as commodities subject to market whims, but as critical infrastructure essential to the lifeblood of European society.
